Nemolizumab was well tolerated and provided lasting relief from itching and disease severity while improving quality of life in patients with prurigo nodularis (PN) over 68 weeks. Patients also ...

"These results show – for the first time in a Phase 3 prurigo nodularis trial – that a systemic medicine was able to address the most debilitating symptoms such as itch without broadly ...

ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...